Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Apr;39(4):917–920. doi: 10.1128/aac.39.4.917

Trends in susceptibility of Neisseria gonorrhoeae to ceftriaxone from 1985 through 1991.

J R Schwebke 1, W Whittington 1, R J Rice 1, H H Handsfield 1, J Hale 1, K K Holmes 1
PMCID: PMC162653  PMID: 7785995

Abstract

The antimicrobial susceptibilities of 16,441 gonococcal isolates from Seattle-King County were determined for ceftriaxone, cefoxitin, penicillin G, and tetracycline. From 1985 to 1989, ceftriaxone, in combination with doxycycline, was increasingly used for treatment of gonorrhea, and by 1989, it was used as therapy for > 80% of cases in Seattle-King County. MICs of ceftriaxone correlated significantly (P < 0.001) with those of the other beta-lactam antibodies included in this study. Geometric mean MICs of penicillin G for isolates that did not produce beta-lactamase increased from 1985 to 1991. The geometric mean MICs of cefoxitin, ceftriaxone, and tetracycline began to decline in 1987 but increased in 1990 and 1991. The percentage of strains with decreased susceptibility to ceftriaxone (MIC, 0.06 to 0.25 microgram/ml) rose from 0.3% in 1985 to 5.3% in 1987 but subsequently declined steadily to 2.6% in 1991, despite increased use of ceftriaxone as routine therapy for gonorrhea. Changes in patterns of antimicrobial susceptibility may be related not only to antimicrobial selection pressures but also to less well understood population shifts among Neisseria gonorrhoeae strains within a community.

Full Text

The Full Text of this article is available as a PDF (211.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boslego J. W., Tramont E. C., Takafuji E. T., Diniega B. M., Mitchell B. S., Small J. W., Khan W. N., Stein D. C. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med. 1987 Jul 30;317(5):272–278. doi: 10.1056/NEJM198707303170504. [DOI] [PubMed] [Google Scholar]
  2. Cannon J. G., Sparling P. F. The genetics of the gonococcus. Annu Rev Microbiol. 1984;38:111–133. doi: 10.1146/annurev.mi.38.100184.000551. [DOI] [PubMed] [Google Scholar]
  3. Dillon J. A., Yeung K. H. Beta-lactamase plasmids and chromosomally mediated antibiotic resistance in pathogenic Neisseria species. Clin Microbiol Rev. 1989 Apr;2 (Suppl):S125–S133. doi: 10.1128/cmr.2.suppl.s125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Faruki H., Kohmescher R. N., McKinney W. P., Sparling P. F. A community-based outbreak of infection with penicillin-resistant Neisseria gonorrhoeae not producing penicillinase (chromosomally mediated resistance). N Engl J Med. 1985 Sep 5;313(10):607–611. doi: 10.1056/NEJM198509053131004. [DOI] [PubMed] [Google Scholar]
  5. Faruki H., Sparling P. F. Genetics of resistance in a non-beta-lactamase-producing gonococcus with relatively high-level penicillin resistance. Antimicrob Agents Chemother. 1986 Dec;30(6):856–860. doi: 10.1128/aac.30.6.856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Handsfield H. H., Hook E. W., 3rd Ceftriaxone for treatment of uncomplicated gonorrhea: routine use of a single 125-mg dose in a sexually transmitted disease clinic. Sex Transm Dis. 1987 Oct-Dec;14(4):227–230. [PubMed] [Google Scholar]
  7. Handsfield H. H., McCormack W. M., Hook E. W., 3rd, Douglas J. M., Jr, Covino J. M., Verdon M. S., Reichart C. A., Ehret J. M. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. N Engl J Med. 1991 Nov 7;325(19):1337–1341. doi: 10.1056/NEJM199111073251903. [DOI] [PubMed] [Google Scholar]
  8. Handsfield H. H., Rice R. J., Roberts M. C., Holmes K. K. Localized outbreak of penicillinase-producing Neisseria gonorrhoeae. Paradigm for introduction and spread of gonorrhea in a community. JAMA. 1989 Apr 28;261(16):2357–2361. [PubMed] [Google Scholar]
  9. Handsfield H. H., Sandström E. G., Knapp J. S., Perine P. L., Whittington W. L., Sayers D. E., Holmes K. K. Epidemiology of penicillinase-producing Neisseria gonorrhoeae infections: analysis by auxotyping and serogrouping. N Engl J Med. 1982 Apr 22;306(16):950–954. doi: 10.1056/NEJM198204223061602. [DOI] [PubMed] [Google Scholar]
  10. Ison C. A., Gedney J., Easmon C. S. Chromosomal resistance of gonococci to antibiotics. Genitourin Med. 1987 Aug;63(4):239–243. doi: 10.1136/sti.63.4.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Jacoby G. A., Medeiros A. A. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 1991 Sep;35(9):1697–1704. doi: 10.1128/aac.35.9.1697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Jones R. N., Gavan T. L., Thornsberry C., Fuchs P. C., Gerlach E. H., Knapp J. S., Murray P., Washington J. A., 2nd Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline. J Clin Microbiol. 1989 Dec;27(12):2758–2766. doi: 10.1128/jcm.27.12.2758-2766.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Judson F. N. Treatment of uncomplicated gonorrhea with ceftriaxone: a review. Sex Transm Dis. 1986 Jul-Sep;13(3 Suppl):199–202. doi: 10.1097/00007435-198607000-00021. [DOI] [PubMed] [Google Scholar]
  14. Knapp J. S., Holmes K. K., Bonin P., Hook E. W., 3rd Epidemiology of gonorrhea: distribution and temporal changes in auxotype/serovar classes of Neisseria gonorrhoeae. Sex Transm Dis. 1987 Jan-Mar;14(1):26–32. [PubMed] [Google Scholar]
  15. Knapp J. S., Tam M. R., Nowinski R. C., Holmes K. K., Sandström E. G. Serological classification of Neisseria gonorrhoeae with use of monoclonal antibodies to gonococcal outer membrane protein I. J Infect Dis. 1984 Jul;150(1):44–48. doi: 10.1093/infdis/150.1.44. [DOI] [PubMed] [Google Scholar]
  16. Rice R. J., Biddle J. W., JeanLouis Y. A., DeWitt W. E., Blount J. H., Morse S. A. Chromosomally mediated resistance in Neisseria gonorrhoeae in the United States: results of surveillance and reporting, 1983-1984. J Infect Dis. 1986 Feb;153(2):340–345. doi: 10.1093/infdis/153.2.340. [DOI] [PubMed] [Google Scholar]
  17. Roddy R. E., Handsfield H. H., Hook E. W., 3rd Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men. Antimicrob Agents Chemother. 1986 Aug;30(2):267–269. doi: 10.1128/aac.30.2.267. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Schwarcz S. K., Zenilman J. M., Schnell D., Knapp J. S., Hook E. W., 3rd, Thompson S., Judson F. N., Holmes K. K. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project. JAMA. 1990 Sep 19;264(11):1413–1417. [PubMed] [Google Scholar]
  19. Sparling P. F. Antibiotic resistance in Neisseria gonorrhoeae. Med Clin North Am. 1972 Sep;56(5):1133–1144. doi: 10.1016/s0025-7125(16)32339-2. [DOI] [PubMed] [Google Scholar]
  20. Woodford N., Bindayna K. M., Easmon C. S., Ison C. A. Associations between serotype and susceptibility to antibiotics of Neisseria gonorrhoeae. Genitourin Med. 1989 Apr;65(2):86–91. doi: 10.1136/sti.65.2.86. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES